Bruton’s Tyrosine Kinase Degrader CLL Treatment – Novel Drug Shows Promise

Summary of the Article: Bexobrutideg Shows Promise in Chronic Lymphocytic Leukemia

This article discusses promising early results from a phase 1a study of bexobrutideg, a ⁣novel Bruton’s tyrosine kinase (BTK) degrader, for patients with relapsed⁢ or refractory chronic lymphocytic leukemia (CLL).

Key Findings:

* High Response ⁤Rate: ‍An overall ⁣response rate of⁢ 80.9% was observed in 47 ⁣response-evaluable patients, with all responses being partial responses.
* Good Tolerability: Bexobrutideg was well-tolerated at all doses tested,with a median⁢ treatment duration of 7 months.
* Novel Approach: The⁢ study explores ‍whether degrading the BTK molecule is more effective than ‍simply inhibiting it, building⁢ on the⁣ success of existing BTK inhibitors.
* Study Details: 48 patients with CLL or small lymphocytic lymphoma were treated with varying doses ⁣of ⁢bexobrutideg (50mg -⁢ 600mg daily).Most participants received 600mg.

Expert Opinion:

Joshua Brody, MD, director of the lymphoma immunotherapy program at the tisch Cancer Institute at Mount Sinai, calls the progress of degraders “huge” and emphasizes the importance of answering the question of whether BTK degradation is ‍superior to inhibition. He describes the results ⁣as “incredibly promising,” though further follow-up is needed.

Source:

The information comes from a presentation at the Society of Hematologic Oncology’s Annual Meeting (SOHO, Sept. 3-6, 2025, Houston) and Healio Interviews.

Disclosure:

The Brody Lab receives funding from ADC Therapeutics, AstraZeneca, Genentech, Merck and Pfizer.